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ReviewFriends or Foes? Emerging Impacts
of Biological ToxinsGraeme C. Clark,1,* Nicholas R. Casewell,2 Christopher T. Elliott,3 Alan L. Harvey,4
Andrew G. Jamieson,5 Peter N. Strong,6 and Andrew D. Turner7Highlights
Toxins with nanomolar binding afﬁ-
nities and exquisite target speciﬁcities
can be powerful tools for fundamental
cellular science and medicine.
Improved omic techniques can identify
toxins from within genomes or
venoms, aiding the identiﬁcation of
new naturally occurring molecules,
which are more effective drugs/tools
in the future.
Drug discovery projects have identiﬁedToxins are substances produced from biological sources (e.g., animal, plants,
microorganisms) that have deleterious effects on a living organism. Despite the
obvious health concerns of being exposed to toxins, they are having substantial
positive impacts in a number of industrial sectors. Several toxin-derived prod-
ucts are approved for clinical, veterinary, or agrochemical uses. This review
sets out the case for toxins as ‘friends’ that are providing the basis of novel
medicines, insecticides, and even nucleic acid sequencing technologies. We
also discuss emerging toxins (‘foes’) that are becoming increasingly prevalent
in a range of contexts through climate change and the globalisation of food
supply chains and that ultimately pose a risk to health.toxins with unique properties and, as
exempliﬁed by botulinum toxin and
clinical/cosmetic use, can have a bil-
lion dollar market potential.
Innovative ‘eco-friendly’ insecticides
derived from venoms are being used
in the agricultural sector, exemplifying
the diverse potential applications of
well-characterised toxins.
Climate change is signiﬁcantly altering
the global distribution of biological tox-
ins, potentially increasing both their
discovery and also the likelihood of
them affecting humans and animals.
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In the natural world, toxins are employed for diverse purposes, from the prey-incapacitating
molecules found in snake, spider, and cone snail venom, to the defensive compounds
harboured by numerous poisonous plant and animal species. While the consequences of
human intoxication can be severe (Box 1), the functional diversity of biological toxins has led to
their frequent use as experimental tools for studying physiological and pharmacological
mechanisms (e.g., synaptic transmission, ion channel subtypes) (Figure 1).
Toxinology involves the identiﬁcation, characterisation, production, and engineering of biologi-
cal toxins along with their application or repurposing as research tools and clinical products. As
such, toxinology encompasses the study of the evolution, chemistry, biology, and clinical
effects of toxins and includes potential biotechnological and/or therapeutic applications.
Experimental applications of toxins as tools for physiologists go back a long time, including
Claude Bernard’s experiments in the 1800s with curare to demonstrate the existence of
chemical signalling between nerves and muscles [2], and Henry Dale’s use of muscarine
and nicotine to show different subtypes of receptors for acetylcholine [3]. Snake toxins were
critical for the ﬁrst isolation of a receptor for a neurotransmitter [a-bungarotoxin and nicotinic
acetylcholine receptors (nAChRs)] [4]. Recently, peptide toxins have been very useful in teasing
out the functional importance of different subtypes of ion channels that are critical for neuronal
function and cellular signalling [5–7].
An increasing number of toxins are now transitioning from the laboratory to the clinic and the
balance of research in this aspect of toxinology is shifting from the classical development of
anti-toxins and anti-venoms towards drug discovery [8,9]. The attraction of toxins for drug
discovery lies in their often unique selectivity of their biological effects coupled with high
potency. Toxic plant alkaloids were the ﬁrst source of toxin-derived therapeutics, notablyTrends in Biochemical Sciences, April 2019, Vol. 44, No. 4 https://doi.org/10.1016/j.tibs.2018.12.004 365
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Box 1. Examples of Venom and Toxin Effects in Humans
Toxins are produced by many types of organisms and upon intoxication can affect cellular functioning in many different
ways (Figure 1). When ingested (i.e., for bacterial, fungal, and plant toxins) or injected (i.e., by snakes, spiders, or other
animal venoms), toxins can cause serious illness and death. Exposure to toxins of bacterial origin can cause many
potentially fatal diseases, including cholera, tetanus, and botulism, and they also contribute to the severe pathologies
associated with sepsis and necrotising fasciitis. Tetrodotoxin is generally thought to be produced by bacteria in puffer
ﬁsh; if ingested, it can block Na+ channels in nerves and cause muscular paralysis that can be fatal. Fungal toxins include
the aﬂatoxins that can contaminate cereals; they are associated with chronic liver disease and liver cancer. All venoms
are diverse mixtures of different toxins, so the effects in humans can be complex and variable [1]. Scorpion venoms
contain many toxins that affect ion channels in nerves to cause overstimulation of neuronal signalling that can lead to
paralysis. The symptoms of snakebite vary depending on the type of snake. Broadly, elapid snakes (such as cobras and
mambas) mainly have neurotoxins that cause neuromuscular paralysis and, potentially, respiratory failure. Viperid
snakes (vipers, adders, rattlesnakes) have some components that affect blood clotting and other toxins that cause
severe tissue damage. The effects can be fatal or, in the case of local tissue damage, result in life-long disabilities.digoxin in atrial ﬁbrillation and heart failure, and tubocurarine as a selective muscle relaxant for
use as an adjunct to general anaesthetics in major surgery [8]. Snake venoms have also
provided leads that have been transformed into successful therapeutics: captopril, the ﬁrst
orally active inhibitor of angiotensin-converting enzyme (ACE), was derived from studies on
small peptides known as bradykinin-potentiating peptides, isolated from the venom of the
snake Bothrops jararaca [10]. Captopril led to major advances in the treatment of patients with
high blood pressure and heart failure. Several other venom-derived peptides have led to
approved medicines (Table 1), and toxin-related peptides are also being extensively studied
for many neurological indications [16]. Perhaps the most surprising toxin that has found medical
uses is botulinum toxin, probably the most potent toxin known, but with applications in various
movement disorders and migraine, as well as its familiar cosmetic use [17,18] (Box 2).
Collectively, by providing worked examples and case studies, this review article highlights how
research in the ﬁeld of toxinology is now booming and ﬁrstly covers the drivers (e.g., techno-
logical, climatic) that are aiding and/or stimulating developments in this area. We here demon-
strate the considerable impact that toxins are having in a diverse range of sectors (i.e.,
biosciences, animal/human healthcare, food/water safety) and every year new, emerging
toxins are identiﬁed or are in development for an increasingly diverse range of applications.
This trend will only increase in the future and we have set out a balanced case for why society
should now consider toxins as both ‘friends and foes’.
Technological Enablers for Toxinology
Technological developments, particularly in the ﬁeld of ‘omics’, have greatly facilitated our knowl-
edge of how organisms (e.g., cone snails, snakes, spiders) produce toxins and how these compo-
nents have evolved [22–24]. Transcriptomics and proteomics (see Glossary) have also enabled
the sensitive detection and identiﬁcation of toxins, including those that exhibit unique/speciﬁc
biological properties. These high-throughput omic approaches have been successfully used as
mining tools to identifyaround2000nucleotideand8000proteinuniquesequencesfromwithincone
snail venoms alone [24]; the vast majority are yet to be fully characterised for their structural or
physiological properties. Current enabling technologies span the molecular, proteomic, chemical,
biochemical, and structural ﬁelds. For example, toxin identiﬁcation has been greatly facilitated by
high-throughput genomic and transcriptomic sequencing, highly sensitive and speciﬁc mass
spectrometric chemical detection, and comprehensive proteomic analyses [9,25,26].
One of the enduring challenges that remains for omic approaches is the availability of in silico
systems that either predict the presence of a toxin with a completely new mechanism of action
or can identify the potential for off-target effects that might limit the molecule’s usefulness as a366 Trends in Biochemical Sciences, April 2019, Vol. 44, No. 4
Glossary
Antimicrobial peptides (AMPs):
are used by multicellular organisms
to prevent the development of
infection, either directly by disrupting
the microbial membranes (e.g.,
bacteria, virus) or indirectly by
stimulating an immune response.
They are typically short (<50 amino
acids), amphipathic alpha-helical
peptides, incorporating positively
charged amino acids on one side
and hydrophobic residues on the
other.
Biosecurity: a ﬁeld involved in the
analysis and management of the
risks of the release of plant pests,
animal pests and diseases,
zoonoses, and genetically modiﬁed
organisms, and the introduction and
management of invasive alien
species and genotypes. Adapted
from the Food and Agriculture
Organization of the United Nations.
(http://www.fao.org/biosecurity/).
Biostability and bioavailability:
refers to speciﬁc characteristics of a
drug with regard to what proportion
of the original dose reaches the
circulatory system (bioavailability) and
how long that therapy remains active
in the blood (biostability).
Eutrophication: refers to the
process by which there is an
increase in the nutrient and mineral
content of a body of water, triggering
the growth of plants and algae.
HAB: harmful algal blooms that
predominantly occur due to
overgrowth of cyanobacteria, leading
to severe oxygen depletion of water
and the release of toxins that pose a
threat to health of humans and
aquatic ecosystems.
Lipid rafts: microdomains within
cellular plasma membranes that
contain a concentration of protein
receptors and/or glycosphingolipids
and are thought to be important for
key processes (e.g., membrane
ﬂuidity, cell signalling, receptor
trafﬁcking).
One Health: as deﬁned by the
Centres for Disease Control, One
Health recognises that the health of
people is connected to the health of
animals and the environment.
Parenteral: administration of a
treatment via a needle.
Peptidomimetic: molecules that
mimic the structure and/or function
of a peptide. Typically, these areresearch tool or putative drug therapy. For example, the current limitations of cutting edge tools
such as predictive algorithms (e.g., Conosorter or Conoserver) were illustrated when, in an
attempt to identify toxins from the venom ducts of cone snails using genetic or transcriptomic
data, it was found that that only a proportion of the putative molecules were ultimately found
within the proteome [24].
Analytical at-line nanofractionation techniques, which couple high-throughput functional screen-
ing with compound identiﬁcation, have proven to be useful tools for identifying bioactives from
complex mixtures [27,28]. Improvements in NMR and ambient mass spectrometry provide the
potential for the detection and identiﬁcation of toxins in foodstuff (see Food and Water Biosafety/
Security Sectors). In the ﬁeld of structural biology, cryo-electron microscopy (cryo-EM) has
advanced our understanding of how toxins interact at the molecular level with their targets such
as physiological receptors [29,30]. Further,high-speed atomic force spectroscopy (HS-AFM) now
allows the interaction of toxins with phospholipids to be studied in real time, providing insights into
the functioning and dynamic nature of cell surfaces (see Biosciences Sector).
Perhaps most importantly, many of these approaches have dramatically reduced the amount of
starting material required for analysis. Many previously uncharacterised toxin-containing sam-
ples (e.g., venoms of small invertebrate species, aquatic toxins produced by marine and
freshwater algae or bacteria) are now amenable for compositional and functional characteri-
sation [31–33]. Consequently, several companies now provide libraries of diverse toxins for
pharmaceutical screening purposes, and thus toxins remain interesting targets for therapeutic
and diagnostic translation [8].
The widespread use of toxins as experimental tools has been further facilitated by develop-
ments in synthetic chemistry and recombinant expression systems (e.g., bacteria, yeast)
making production of research scale quantities of toxins easier. Solid phase synthesis of
peptide toxins using orthogonal protection strategies now provides a robust and efﬁcient
method to produce toxins with the speciﬁc disulﬁde folding networks that are essential for
bioactivity [34,35]. Recombinant expression systems have also enabled recent advances, as
exempliﬁed by successful production in Escherichia coli of complex disulﬁde bond-rich toxins
that require post-translational modiﬁcation [36]. Whilst the isolation from natural sources or
production of synthetic or modiﬁed versions of toxins is certainly becoming less challenging for
research-scale quantities of material, issues still remain about how to produce the quantities of
toxin required for commercialisation of a product.
Toxins as Friends: Advancing Basic Science and Leading to Commercial
Developments
Enabling technologies have opened up the potential for identifying, characterising, and exploit-
ing a cornucopia of new and emerging toxins. The following sections highlight the positive
impacts these diverse molecules can have in a range of sectors.
Biosciences Sector
Toxins have played an important role in understanding many fundamental physiological
processes. In particular, they have helped to elucidate the structure and function of mem-
branes, membrane proteins, and transmembrane signalling.
Ion Channels and the Nervous System
The highly selective binding of peptide toxins to sodium (NaV), potassium (KV), or calcium (CaV)
ion channels has led to their use as exquisitely sensitive tools for studying neural functionTrends in Biochemical Sciences, April 2019, Vol. 44, No. 4 367
bioinspired small molecules or
biopolymers that are derived from
peptides.
Phage display: an approach where
a gene of interest is cloned into the
gene of a phage that encodes a coat
protein. Upon expression of the
protein from the gene, it is displayed
on the surface of the phage, allowing
rapid, high-throughput screening
(‘panning’) for proteins that bind to
the target of interest (i.e., DNA/
protein receptor).
PSP: paralytic shellﬁsh poisoning
syndrome experienced following
consumption of food products
naturally contaminated with saxitoxin
produced by algal blooms.
Recombinant expression
systems: represents the cloning of a
gene encoding a toxin into a plasmid
and subsequently into commercial
bacterial/yeast strains (e.g.,
Escherichia coli, Pichia pastoris) or
mammalian cells optimised for
protein production.
SNARE proteins: a complex of
proteins that form vesicles and that
are essential for neurotransmitter
release at the presynaptic cleft and
nerve cell functioning.
Solid phase synthesis: the
stepwise chemical synthesis of a
peptide from amino acid building
blocks on a solid support, most
commonly polystyrene beads.
Strabismus: a medical condition
that can be associated with a
speciﬁc muscle dysfunction, resulting
in both eyes being unable to align
with each other on an object of
interest.
Transcriptomics and proteomics:
often referred to as ‘omics’ and
involve high-throughput techniques
to characterise the composition of
these separate molecules of RNA or
protein that make up the sample.
Zoonotic: an infectious disease that
can be transmitted to humans from
animals.(Figure 2) [5–7,9,16]. In addition, several reports and ﬁled patents highlighted the potential to
exploit the bioactivity of various marine toxins, including saxitoxins, tetrodotoxins (TTX),
yessotoxins, palytoxins, brevetoxins, and cyclic imines, for this purpose [37]. In particular,
TTX has routine use in the laboratory for the study of NaV ion channels. The success of these
products has led to synthetic toxins being developed as tools for chemical biology that possess
higher afﬁnity and speciﬁcity than the natural molecule. To aid the identiﬁcation and develop-
ment of these novel toxins, high-throughput and/or logical design strategies are used. One
such high-throughput method is phage display. The production of peptide libraries (in the
millions of compounds) with variable sequence and based on known toxin scaffolds is an
effective strategy to identify potent and selective ligands. This approach successfully identiﬁed
a potent and selective toxin probe using a molecular scaffold based on sea anemone toxin ShK
speciﬁc for the orphan KcsA potassium channel, dysfunctions of which have been linked to
autoimmunity [38,39]. A further example is based on a conotoxin from the venom of one of the
hundreds of species of marine cone snails; Clark and coworkers designed an a-conotoxin
cVc1.1 analogue with >8000-fold selectivity for calcium channels over a9a10 nAChRs. This
molecule was used in a mouse model of chronic visceral hypersensitivity to demonstrate that
the analgesic effects of the parent toxin were due to a calcium channel block rather than block
of acetylcholine receptors [40].
Toxin peptides can be easily modiﬁed (e.g., radioactive, ﬂuorescent) to provide analogues to
facilitate the characterisation of cell surface receptors and ion channels. Chlorotoxin from the
venom of the scorpion Leiurus quinquestriatus, has been chemically conjugated to a dye and
used as ‘tumour paint’ because the toxin serendipitously binds selectively to neuronal cancer
cells by providing a clear demarcation between cancerous and normal tissue [41]. Peptide
toxins can also be structurally modiﬁed to provide peptidomimetics incorporating function-
ality (e.g., conformational constraints, non-native amino acids) to overcome some of their
physicochemical limitations, including plasma instability and cell permeability, therefore
increasing their overall range of applications within the laboratory [42].
Membrane Structure and Function
Many pathogenic bacteria owe their clinical effects to pore-forming toxins (PFTs) (Figure 1).
Toxins that form membrane pores have therefore been studied to determine the mechanism of
this membrane disruption. PFTs are also found in diverse eukaryotes ranging from the bee
venom cytotoxin mellitin from Apis mellifera to actinoporins from sea anemones. More recently,
antimicrobial peptides (AMPs) from snake and scorpion venoms have been recognised as
pore formers. The temporal resolution of mechanisms of action of PFTs (e.g., helping us to
understand differences between how peptides insert into membranes) have been improved
using the patch clamp technique, initially using artiﬁcial lipid membranes and more recently
under physiological conditions using mammalian cells [43,44].
The understanding of toxin–membrane and toxin–membrane protein interactions at a molec-
ular level is undergoing a transformative shift, with the development of cryo-EM allowing for
high-resolution structural determination without the need for growing crystals. Lysenin, a toxin
from the body ﬂuid of the earthworm Eisenia fetida, belongs to the aerolysin family of small
b-pore-forming toxins [45]. The water-soluble monomeric protein oligomerises in contact with
sphingomyelin and forms transmembrane pores [46]. Using cryo-EM, an atomic model of the
pore formed in bilayer membranes by the oligomeric protein has been determined [47].
As stated earlier, HS-AFM is a technique that allows structural resolution of molecules to be
determined at a nanoscale level in real-time. HS-AFM, in conjunction with quartz crystal368 Trends in Biochemical Sciences, April 2019, Vol. 44, No. 4
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Table 1. FDA Approved Venom-Derived Therapies for Treating Human Diseases
Drug Indication Lead source Molecular function Chemical structure Refs
Captopril Hypertension and congestive
heart failure
Bothrops jararaca Angiotensin-converting enzyme
(ACE) inhibitor
Small molecule [11]
Eptiﬁbatide Acute coronary syndrome Sistrurus miliarius barbouri aIIbb3 receptor Cyclic disulﬁde-constrained
peptide
[12]
Tiroﬁban Acute coronary syndrome Echis carinatus aIIbb3 receptor Small molecule [13]
Ziconotide Severe chronic pain Conus magus N-type CaV Cyclic disulﬁde-constrained
peptide
[14]
Exenatide Type 2 diabetes Gila monster (Heloderma suspectum) Glucagon-like peptide-1 receptor 39-residue linear peptide [15]
Box 2. Case Study: Botulinum Toxin from Biothreat to Wonder Drug
The infamy of botulinum toxin (Latin-derived meaning: sausage poisoning) arose from food poisoning cases in Germany
as early as the 1900s. Recognised as the most poisonous natural substance known to man, picogram quantities are
lethal in murine models [19]. Interest from a number of regimes led to the toxin becoming a molecule of concern from a
defence perspective [20]. Nowadays, botulinum toxin is most commonly associated with cosmetic applications (e.g.,
antiwrinkling) and is responsible for astonishing global sales of around $3 billion per annum for one product (Botox1)
alone.
Botulinum toxin is a 150 kDa A-B subunit toxin (Figure 1). Binding by the B-subunit to the presynaptic membrane of
neuromuscular junctions and, by using the zinc metalloprotease catalytic activity of the A-subunit, the toxin cleaves
SNARE proteins involved in the release of the neurotransmitter acetylcholine. The result is ﬂaccid paralysis of muscle,
initially affecting the peripheral nervous system, with death associated with respiratory failure.
Despite being overshadowed by its use in the cosmetics industry, the clinical applications of botulinum toxin have been
game changing for the treatment of various neuromuscular disorders. Following FDA approval of the ﬁrst product in
1978 for the treatment of strabismus, a range of other molecules have been developed for use in humans (Table 2).
Each has a subtly different composition with either toxin serotypes A and B (of the seven botulinum toxins in total;
serotypes A–G) being the main active component, alongside various ancillary proteins that support either the stability or
mode of action of the toxin [21]. Their use has revolutionised the treatment of movement disorders (‘dystonia’) in both
adults and children, in most cases reducing/removing the need for corrective surgery. Further recent development has
highlighted the potential for the toxin to treat a wider range of neurological conditions, as evidenced by its approval for
use in the EU and North America for treating chronic migraines in adults.microbalance dissipation, has visualised the formation of highly branched membrane defects
when AMPs from scorpion venom interact with planar lipid membranes, allowing the separation
of fast (within 200 s) and slow (up to 25 min) toxin–membrane interactions [48]. Labelling
functionalized AFM tips with toxins such as lysenin or the D4 domain of Q-toxin (cholesterol-
speciﬁc) has allowed the identiﬁcation of speciﬁc domains of sphingomyelin and cholesterol in
bilayer membranes without the need for ﬁxation or labelling steps, both supporting the concept
of lipid rafts and offering the possibility of directly observing lipid assemblies in native cells [49].
Nucleic Acid Squence Analysis
Nanopores, created by pore-forming membrane proteins in electrically insulated artiﬁcial
membranes, can be engineered to detect single molecules passing through the channel theyFigure 1. The Many Sizes, Shapes, and Mechanisms of Action of Toxins. (A) Large toxins and (B) small molecule toxins. Typically, single celled prokaryotes (e.
g., bacteria) produce larger toxins as a consequence of having simple protein-folding machinery; however, often small amounts can be very toxic (e.g., botulinum toxin).
In contrast, eukaryotes (e.g., spiders, cone snails) can produce incredibly small peptides with highly complicated structures held together with multiple disulﬁde bonds,
creating molecules with high speciﬁcity and avidity for their target cell/substrate. APC, Antigen presenting cell; PSP, paralytic shellﬁsh poisoning; rmu, relative mass unit.
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Figure 2. Examples of Voltage-Gated or Ligand-Binding Ion Channels Targeted by Toxins. Only a small subset of ion channel types that are pertinent to the
review are highlighted here. Differences in the composition and amino acid sequences of a- and b-subunits of ion channels dictate the nomenclature (e.g., NaV1.1–1.9).
Many more exist that provide a diversity of physiological processes. For example, there are toxins with selective actions on calcium-activated potassium channels,
inward rectiﬁer potassium channels, chloride channels, acid sensing ion channels, transient receptor potential channels, and ionotropic glutamate receptors. *(+) Open
channels and () closed. nAChR, nicotinic acetylcholine receptor.form; more speciﬁcally by monitoring voltage-dependent changes in ion currents. The differ-
ential detection of individual DNA bases passing through engineered a-haemolysin toxin
nanopores has led to the development of revolutionary rapid DNA single molecule sequencers
termed the MinION [50,51].
Collectively, the development of new technologies, in parallel with efﬁcient chemistries to
produce toxin peptides and peptidomimetics, has led to an increase in the applications in
bioscience research that shows no signs of slowing.
Animal and Human Healthcare Sectors
As a result of their diverse and often highly selective functional activities on important physio-
logical processes, toxins have also received attention as potential therapeutics. Indeed,
toxinology has already demonstrated impact within a clinical setting for the treatment ofTrends in Biochemical Sciences, April 2019, Vol. 44, No. 4 371
cardiovascular disease (see Toxins and Toxinology). Some emerging areas of interest are in the
treatment of pain, as immunotherapies, and for countering antimicrobial resistance (AMR). In
particular, venom extracts from species of cone snail, spider, snake, and lizard represent a
goldmine of hundreds to thousands of bioactive compounds with peptides as the main
components. Typically, the cocktails of peptides employed by venomous species have multiple
targets in the body and are designed to immobilise their prey by subverting or inactivating
critical physiological pathways/processes. Consequently, research to determine the targets
and assess potential applications of these peptide toxins has seen rapid growth in the past few
decades given their pharmacological potential [16]. Five peptide toxin-derived drugs from the
viper family of snakes (i.e., captopril, eptiﬁbatide, tiroﬁban), a cone snail (i.e., ziconotide), and a
lizard (i.e., exenatide) are currently approved by the FDA for clinical use for a diverse range of
medical conditions, including blood pressure, pain, and diabetes (Table 1; Box 3). Many more
are in preclinical development, including one from a sea anemone for use in autoimmune
diseases (Box 3). There is also a plethora of predominantly enzymatic, snake venom-derived
proteins that target natural processes in the circulatory system (i.e., clotting, coagulation)
that are in use or being developed as drugs to treat various indications, from heart disease to
cancer [52,53].
Pain Therapeutics and Congenital Neurological Conditions
Peptide toxins have potential applications for the treatment of pain with the advantage that they
lack the addiction proﬁles observed with opiate drugs such as morphine. Ziconotide, a
synthetic version of a peptide found in the venom of the marine cone snail Conus magus,
is licensed for use in the treatment of severe and chronic pain (Table 2). The mechanism of
action is as a selective N-type voltage-gated calcium channel blocker (Figure 2). However,
ziconotide is administered intrathecally (i.e., directly into the spinal ﬂuid) due to severe side
effects on oral or intravenous administration. This has prevented widespread therapeutic use of
ziconotide and driven current research to focus on developing peptide toxin-derived thera-
peutics with improved bioavailability and better selectivity [60]. There is clearly potential for the
discovery of highly selective and potent peptide toxins that target neuronal ion channels or
receptors as analgesics.
Spider venoms predominantly target the nervous system and offer signiﬁcant potential for the
identiﬁcation of new treatments for pain or neurological disorders. Some research in this areaBox 3. Toxins from Land and Sea to the Clinic
The Gila monster (Heloderma suspectum) is a venomous lizard found in south-west USA and north-east Mexico. The
venom of this reptile contains many bioactive peptides and enzymes, including exendins, homologues of the mam-
malian glucagon-like peptides (GLP). In humans, GLP-1 is released from the gut after eating, triggering increases in
insulin secretion, decreases in glucagon release, slowing gastric emptying, and decreasing appetite: actions that could
contribute to an antidiabetic effect. However, GLP-1 is very rapidly inactivated by dipeptidyl peptidase IV (DPP-IV).
Exendin-4 from Gila monster venom is very resistant to the action of DPP-IV [54] and is therefore much longer acting in
lowering blood glucose than GLP-1. Consequently, synthetic exendin-4 (exenatide; Byetta) was developed by Amylin
Pharmaceuticals for treatment of patients with type 2 diabetes and approved by the FDA in 2005 [55].
The venoms of sea anemones are particularly rich in small peptides that affect sodium and potassium ion channels and
thereby disrupt the normal signalling in the nervous system [56]. A component from venom of the Caribbean sea
anemone Stichodactyla helianthus was ﬁrst noted for its ability to increase neurotransmitter release by blocking voltage-
dependent potassium ion channels [57]. Small structural modiﬁcations gave a derivative ShK-186 that had very high
potency and speciﬁcity for one subtype of potassium channel, KV 1.3. This was signiﬁcant because activation of that
channel in memory T cells on lymphocytes drives some autoimmune diseases. Studies in animal models of multiple
sclerosis and rheumatoid arthritis were positive [58] and ShK-186 was entered into clinical trials by Kineta. Under the
trade name Dalazatide, the compound has successfully completed a clinical trial in patients with psoriasis [59].
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Table 2. Clinically Approved Products and Applications of Botulinum Toxin
Trade name Molecule name (active
serotype in bold)
Company Approved applications
BOTOXJ OnabotulinumtoxinA Allergan, USA Cervical dystonia (neck muscle), severe primary axillary hyperhidrosis (excessive
underarm sweating), strabismus (eye alignment), and blepharospasm (eye lid spasm)
associated in patients over 12 years old, overactive bladder, muscle stiffness around
joints, and chronic migraine
Dysport AbobotulinumtoxinA Ipsen, France Cervical dystonia, facial wrinkles, and upper limb spasticity
Myobloc/Neurobloc RimabotulinumtoxinB US WorldMeds Cervical dystonia
Xeomin/Bocouture IncobotulinumtoxinA Merz, Germany Cervical dystonia, blepharospasm, facial wrinkles, upper limb spasticity, excessive
salivationfocused on targeting NaV1.7 channels on neurons (Figure 2). Amgen tested the GpTx-1
peptide, discovered by high-throughput screening of fractionated venom from the tarantula
Grammostola porteri [61]. Subsequent structure–activity relationship studies led to the devel-
opment of potent analogues with excellent selectivity for human NaV1.7 over NaV1.4, which
controls excitability of skeletal muscle, and NaV1.5, which is found predominantly in cardiac
muscle. This demonstrates the power of logical, structure-based molecular design to improve
upon a natural toxin scaffold. In addition, a peptide from the venom of the spider Heteroscodra
maculata, termed Hm1a, has been found to speciﬁcally target NaV1.1 channels and was initially
investigated for treating mechanical pain [6]. More recent preclinical research has highlighted
the potential of this molecule for treating congenital neurological conditions such as epilepsy:
intracerebroventricular administration of Hm1a prevented seizures and premature death in
mice [62]. Peptides called mambalgins from the venom of the black mamba snake Dendroaspis
polylepis act speciﬁcally on acid-sensing ion channels and have also shown promise in
reducing pain in preclinical studies [5]. Ultimately, to be successful drugs in a clinical setting,
these molecules will have to be suitable for oral or intravenous administration as well as having
better therapeutic windows, and thus safety proﬁles, than currently available drugs.
Novel Antimicrobials
AMR amongst pathogenic bacteria, fungi, and parasites is an increasing issue that spans both
animal and human healthcare and has led to the creation of the ‘One Health’ Initiatives (http://
www.onehealthinitiative.com/mission.php and https://www.cdc.gov/onehealth/basics/index.
html) [63]. AMR may be triggered by inappropriate or excessive antibiotic prescription in the
clinic, or through aggressive use in an agricultural setting (i.e., antibiotic growth promoters in
bovine or poultry feeds) contributing to the development of zoonotic diseases from pathogenic
AMR strains. There is an urgent need for new therapeutic molecules and/or approaches to treat
infectious diseases that exhibit resistance to conventional treatments [64,65]. Many AMPs have
been isolated from the venom of diverse organisms, including ants, bees, wasps, centipedes,
scorpions, spiders, snakes, and cone snails [66]. All have demonstrated efﬁcacy in the test tube
towards both gram-negative and -positive bacteria and as topical applications. There is also
emerging evidence of their efﬁcacy in vivo. One recent example demonstrated the recovery of
mice from a lethal bacteraemia caused by clinical methicillin-resistant Staphylococcus aureus
through the administration of an AMP derived from scorpion venom [67]. However, challenges
also remain with respect to the biostability and bioavailability of these AMPs such that some
form of physicochemical optimisation (i.e., PEGylation, peptide cyclisation) are often required,
particularly when considering using routes of administration other than parenteral for peptides
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range of novel antimicrobial properties, including phospholipase A2 (PLA2; Figure 1), metal-
loproteases, and L-amino acid oxidases (LAAO), and esterases which may lead to antibiotics
with novel mechanisms of action [70]. Antimicrobial activity has also been reported for some
aquatic toxins [37]. Collectively, this work highlights AMR as an emerging theme within
toxinology.
Immune Modulation
The immunomodulatory properties of biological toxins are also being investigated for the
treatment of inﬂammatory disorders, including Crohn’s disease and asthma (i.e., cholera toxin)
[71]. Promising Phase Ib trial results have been obtained for Dalazatide1, an analogue of the
potassium channel blocking toxin ShK from the sea anemone Stichodactyla helianthus, for the
skin condition psoriasis [59] (Box 3). Finally, subunits of enterotoxins from Vibrio, Escherichia,
and Pseudomonas sp. are being used as vaccine adjuvants and have been the subject of a
recent review and patent [72,73]
Agricultural Sector
New discoveries are fuelling the interest in using toxins within the agricultural sector as safe,
environmentally friendly insecticides. Sero-X, licensed as a bee-friendly insecticide in Australia,
contains a cocktail of cyclic peptide toxins isolated from the butterﬂy pea plant and attacks the
gut lining of caterpillars [Australian Government Pesticides and Veterinary Medicines Authority,
2016 (https://apvma.gov.au/sites/default/ﬁles/publication/
21021-public-release-summary-sero-x-insectidice-containing-clitoria-ternatea-extract.pdf)].
Highly speciﬁc insecticides have also been isolated from fungi and spiders. For example, an
environmentally friendly insecticidal peptide related to a calcium channel blocking toxin (v-hex-
atoxin-Hv1a) from the Australian funnel web spider (Atrax robustus) venom has been brought to
the market as ‘Spear1-T’ by Vestaron; molecules from other species of spider are also being
investigated as potential novel pesticides [74].
Toxins as Foes: Emerging Impacts of Climate Change, Biosafety, and
Biosecurity Implications
Aside from their apparent value as physiological and therapeutic tools for the beneﬁt of
mankind, biological toxins are also highly relevant in the wider context of our environment.
The risks to human health as a result of new or emerging toxins appearing naturally are clear.
Equally, as the prevalence of toxins increases in the environment, so does their accessibility and
therefore their potential concern from a biosecurity perspective (e.g., contamination of foods,
water supplies). Whether naturally occurring or manmade, the prediction of potential risk to
humans, rapid identiﬁcation, and/or timely diagnosis of exposure of toxins represents a
signiﬁcant challenge in a range of contexts.
Food and Water Biosafety/Security Sectors
Global climate change means the niches that can be occupied by toxin-producing species of single
cellular organisms, plants, and animals are expanding; particularly those that require warmer climes.
In addition, this, coupled with the encroachment of human habitation into new areas of the world,
collectively increases the potential/incidence of intoxicating events through exposure (e.g., inhala-
tion, ingestion, injection) to either toxins or toxigenic species in the environment.
Aquatic Food and Water Safety
Aquatic food security is signiﬁcantly impacted by environmental change [75]. Marine toxins
responsible for paralytic, amnesic, and diarrhetic shellﬁsh poisoning (PSP, ASP, and DSP) are
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toxin groups with potentially serious health consequences remain largely unregulated. The
majority of toxins are produced naturally by species of marine harmful algal blooms (mHABs),
with others associated with bacteria [76]. Cyanobacterial harmful algal blooms (CHABs) are
distributed widely, most notably in freshwater [77], posing a substantial threat to both drinking
and recreational water. The natural function of aquatic toxins is unclear and research has
primarily focused on the impacts these compounds have on humans. The mechanisms of
marine and freshwater toxicity are extremely diverse, and multiple variants of each toxin group
produce signiﬁcant challenges in monitoring to ensure human safety.
Recent years have shown an increase in the frequency of marine toxin-producing blooms and
bacteria in many areas of the world, together with increasing reports of new or emerging nonprotein
toxins, including polycyclic polyether brevetoxins in New Zealand, ciguatoxins in Spanish ﬁsh, and
polyhydroxylated natural product palytoxin and ovatoxins in Mediterranean mussels, DSP toxins in
the USA, and cyclic imines throughout Europe [78]. There are also prominent examples of the
emergence of unexpected bacterial toxins in UK waters (Box 4). CHABs are also occurring with
increased regularity in both freshwater and marine ecosystems globally [82].
Expansion of marine toxin-producing mHABs over recent decades is well recognised and has
been linked to ballast water transportation, eutrophication, and climate change [76]. Climatic
change in particular is recognised as a key factor concerning the frequency and severity of
natural aquatic toxin occurrence [79,83]. Changes in both mean and extreme values of
temperature, light, ocean acidiﬁcation, wind, precipitation, currents, and nutrients may all
contribute to changes in blooms, including germination and growth rates, geographical
expansion, as well as cell toxicities, shellﬁsh toxicity [83,84], and incidents of human intox-
ications [76]. Similarly, expansion of CHABs is inﬂuenced by many factors, including iron
availability, light, hydrological changes, storm events, drought, precipitation, and industrial
pollution [85]. However, the impacts of eutrophication dominate the literature as the main
causative factors, particularly in conjunction with higher temperatures [86], and almost every
climate change scenario predicts that many freshwater bodies will experience increased
temperatures and longer, more intensive periods of thermal stratiﬁcation, resulting in increased
CHABs occurrence and toxicity [87,88].Box 4. Tetrodotoxin and Vibrio
Tetrodotoxins (TTXs) are responsible for the highest mortality rates in all marine intoxications, being potent low molecular
weight sodium channel-blocking neurotoxins. They accumulate most commonly in tropical and subtropical regions,
particularly in ﬁsh from the Tetraodontidae family such as pufferﬁsh. Unlike other marine toxins, these are produced by
bacteria, notably Vibrio species such as Vibrio parahaemolyticus. Vibrio growth is strongly dependent on high
temperature and low salinity, with increased toxin production anticipated following changes in both parameters,
thereby accelerating the spread of pathogenic bacteria and TTXs in northern latitudes [79]. Following the climate
change related expansion of Vibrio sp. into the marine waters of the southern UK, TTXs were unexpectedly detected in
shellﬁsh such as mussels, oysters, and clams, for the ﬁrst time anywhere in Europe, in some shellﬁsh harvesting sites in
southern England [80]. Subsequently, TTXs have been reported in bivalve molluscs from elsewhere in Europe, including
Greece, the Netherlands, Spain, and Italy, thereby revealing the potential for TTX shellﬁsh poisoning for consumers of
shellﬁsh throughout Europe. The ongoing screening of UK molluscs since the ﬁrst discovery in the UK revealed the
continued presence of TTXs over the following 3 years, but mostly in the warmer summer months and associated with
shallow water, estuarine shellﬁsh beds, with low salinity and warmer waters (temperatures >15 C). As such, there is
strong evidence for an enhanced risk of TTX production during times of higher temperatures and precipitation-triggered
low salinities, both of which are expected as a result of ongoing climatic change in the UK [81]. This case study
represents a unique instance of a new, unexpected, emerging natural aquatic toxin threat, traditionally associated with
warm tropical waters and tropical ﬁsh species, to consumers of shellﬁsh in temperate regions of northern Europe. It
therefore illustrates the potential for dramatic changes to natural toxin populations in the environment, inferring that
many other warmer-water HAB and bacterial toxins should not be excluded from future risk assessment and risk
management programmes.
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Outstanding Questions
What tools can be developed that
would allow toxins with completely
new mechanisms of action to be iden-
tiﬁed? As new technological
approaches fuel potential drug discov-
ery, the next ‘bottleneck’ lies within
availability of suitable models for eval-
uating the biological properties of the
toxin.
How can we easily mass produce
emerging toxins with unique properties
but highly complex structures? For a
molecule to be of value for drug devel-
opment it needs to be manufactured
on an industrial scale, which repre-
sents a signiﬁcant challenge and a
potential barrier to development.
Can peptide-based toxins be adapted
or formulated in order to increase their
longevity of action and targets within
the body? Some peptides will be rap-
idly broken down and cleared from the
body, or are required to be adminis-
tered by injection, which collectively
limits the clinical utility as a treatment.
How and why do algal blooms develop
within the environment? The triggers
for aquatic toxin production are yet
to be elucidated. This makes predict-
ing the emergence of HAB, and there-
fore the forecasting of toxin
production, very difﬁcult.Regulations (e.g., food safety, environmental exposure) are absent for the majority of emerging
aquatic toxins and, given the limited understanding regarding toxin production and occurrence
under climatic change conditions [78], environmental modelling approaches are needed to
forecast spatial and temporal aquatic toxicity and related human health hazards [81]. To do this
we need to link our developing understanding of environmental impacts on toxin production
with the ability to combine improved detection and forecasting systems, including in situ ocean
observation systems, highly speciﬁc and sensitive chemical detection tools, satellite data, and
other biological observations into effective operational modelling regimes [76,82].
Increasing Global Prevalence of Mycotoxin-Producing Species
Mycotoxins are a highly diverse range of toxins produced by toxigenic moulds and are found to
infect a wide variety of agricultural crops, resulting in signiﬁcant risk to crop consumers globally. In
particular, aﬂatoxin- and fumonisin-contaminated foodstuffs represent massive health issues,
especially in the developing world and for the young. High temperatures, elevated CO2, and
humidity/water availability are known in particular to encourage toxic mould formation and thus
climatic change is also having a signiﬁcant impact on mycotoxin presence, resulting in the spread
of mycotoxicity further north within the EU [89], as well as altering the amount of toxin being
produced by toxigenic strains [90]. Cutting edge techniques (e.g., ambient mass spectrometry
and molecular spectroscopy) will be increasingly important for identiﬁcation of contaminated
feeds and foods. More accurate modelling and prediction methods for the impacts of climate
change on mycotoxin production are needed to help address food security concerns [91].
Concluding Remarks and Future Perspectives
Technological developments in omics-based approaches are driving the discovery of new toxins
from an increasing array of organisms (i.e., from bacteria to animals). Challenges remain in the
availabilityof suitable (in vitro, ex vivo, or in vivo) models for characterising the biological properties of
these novel toxins and enabling their subsequent development within the biosciences or healthcare
sectors. There is also an absence of in silico tools that aid the prediction and identiﬁcation of
completely new classes of toxins with unique or distinct mechanisms of action. Similarly, new ways
to assess the potential for ‘off-target’ effects on the body would be of signiﬁcant value when
developing toxins for use in veterinary or clinical applications. Although there are a number of
exceptions, the mass production of natural bioactives (with potential therapeutic beneﬁts) remains
largely challenging given the difﬁculties of producing industrial scale yields of toxins through culture
and/or chemical synthesis (e.g., due to complex disulﬁde bond formations in many peptides). Once
produced, certain peptides may also require chemical modiﬁcation or formulation in order to
improve their pharmacological properties (i.e., biostability, bioavailability), as well as helping to
improve potency and target selectivity, thereby reducing the quantities of material required to
achieve an identical pharmacological effect. Further work is also required in order to improve how
peptide therapeutics will be administered (e.g., formulation towards achieving oral bioavailability
instead of injection; delivery to the central and/or peripheral nervous system).
Within the water and food security sector, there is a fundamental need to develop a ﬁrm
understanding of the relationships that drive climate-induced changes in HAB growth, distri-
bution, and toxicity. In conjunction with a better understanding of the biology, developing new
satellite imaging and analysis techniques will aid in the prediction of algal bloom formations.
Despite the challenges and outstanding research requirements outlined above (also see
Outstanding Questions), for the ﬁeld of toxinology the positive impact that toxins have made
to modern society cannot be denied and that trend looks set to only continue, fuelled by a
number of external factors (e.g., technology developments, commercial opportunities). The376 Trends in Biochemical Sciences, April 2019, Vol. 44, No. 4
Key Figure
Current and Future Drivers in the Field of Toxinology
Current state of
toxinology
Climate change
(i.e., alters geographical distribuƟon
prevalence and areas inhabited by humans) 
Food and water safety/biosecurity
(i.e., natural occurring or intenƟonal 
contaminaƟon)
Commercial drivers                  
(i.e., fuelling drug discovery/development) (i.e., enabling idenƟficaƟon of new toxins)
Technological developments
Future
Increases in the: 
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and/or diversity
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idenƟfied    
(b) Exposures
requiring anƟ-
toxin treatments 
(c) Clinical use
of toxins as
therapies
Human
(e.g., as tools in
cellular funcƟon,
intoxicaƟons or
use as therapies)
Environment
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insecƟcide)
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intoxicaƟons, 
or evoluƟon
in species)
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Figure 3. The ﬁgure highlights the current state of toxinology where the primary focus of research is on biological toxins that directly affect humans, animals, or the
environment. These toxins map to and have a direct impact upon a number of industrial sectors, namely, agriculture, biosciences, food and water biosafety/security as
well as human and animal healthcare. Research on speciﬁc toxins intensiﬁes when they converge to affect multiple sectors. The key, emerging factors are highlighted
that will lead to an increase in the convergence and overall impact of toxins in the future (i.e., positively in green and negatively in red).rapid assimilation of new technical approaches into toxinology and the increasing connections
between research into animal, human, and environmental aspects will be the best approach to
meeting the challenges posed by toxins as both ‘friends and foes’ (Figure 3, Key Figure).
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